Abstract: A method for treating a disease or for treating a symptom of a disease, or a combination of both, the disease being caused or aggravated by microorganisms includes: treating the disease, treating the symptom of the disease, or reducing the duration of the disease, or a combination of both by administering a barrier-forming composition in a therapeutically effective amount to a surface, the surface comprising a mammal mucosa, the mammal being infected with the disease or experiencing symptoms of the disease caused or aggravated by the microorganisms. The barrier-forming composition includes an antimicrobial. Upon administering the composition, the method includes forming a barrier coating on the surface that is active to kill or neutralize microorganisms encountered by the barrier coating. A composition with an agent active for relieving symptoms of a disease is also included.

Abstract: A method for preventing and treating internal infections, e.g., urinary tract infections, caused by catheters is provided, in particular by reduction in catheter-associated biofilms. A coating composition is used to treat the catheter and applied through the catheter into the bladder or other body urinary tract organ to kill or neutralize microorganisms, including biofilms therein. The composition comprises a humectant and an antimicrobial with the antimicrobial including a monoquaternary ammonium compound or pharmaceutically acceptable salt thereof. The coating layer has antimicrobial cidal or static activity for at least about one hour.

Abstract: The disclosure provides compositions and dosage forms for promoting healthy microbial flora in a mammal, for example, a human. The disclosure further provides compositions and dosage forms for disrupting biofilm or preventing formation of biofilm containing pathogenic bacteria and/or pathogenic fungi in a particular region of a subject. The dosage forms contain (i) an isolated non-pathogenic fungal strain that is viable in the region of the subject, (ii) an isolated non-pathogenic bacterial strain that is viable in the region of the subject, and optionally (iii) an enzyme capable of disrupting the biofilm. The present disclosure also provides methods of disrupting a biofilm or preventing formation of a biofilm with such a composition or dosage form, methods of identifying a subject suitable for treatment with such a composition or dosage form, and methods of improving nutrient absorption using such a composition or dosage form.

Abstract: The disclosure provides compositions and dosage forms for promoting healthy microbial flora in a mammal, for example, a human. The disclosure further provides compositions and dosage forms for disrupting biofilm or preventing formation of biofilm containing pathogenic bacteria and/or pathogenic fungi in a particular region of a subject. The dosage forms contain (i) an isolated non-pathogenic fungal strain that is viable in the region of the subject, (ii) an isolated non-pathogenic bacterial strain that is viable in the region of the subject, and optionally (iii) an enzyme capable of disrupting the biofilm. The present disclosure also provides methods of disrupting a biofilm or preventing formation of a biofilm with such a composition or dosage form, methods of identifying a subject suitable for treatment with such a composition or dosage form, and methods of improving nutrient absorption using such a composition or dosage form.

Abstract: The disclosure generally provides a method of balancing microbiome and/or improving nutrient absorption, treating gut inflammation, and/or balancing the level of Firmicutes and Bacteroidetes in the gut of a subject in need thereof, the method comprising consumption by, or administration to the subject of a composition comprising a nutrient in combination with a probiotic composition comprising (i) an isolated non-pathogenic fungal strain and (ii) an isolated non-pathogenic bacterial strain.

Abstract: The disclosure provides compositions and dosage forms for promoting healthy microbial flora in a mammal, for example, a human. The disclosure further provides compositions and dosage forms for disrupting biofilm or preventing formation of biofilm containing pathogenic bacteria and/or pathogenic fungi in a particular region of a subject. The dosage forms contain (i) an isolated non-pathogenic fungal strain that is viable in the region of the subject, (ii) an isolated non-pathogenic bacterial strain that is viable in the region of the subject, and optionally (iii) an enzyme capable of disrupting the biofilm. The present disclosure also provides methods of disrupting a biofilm or preventing formation of a biofilm with such a composition or dosage form, methods of identifying a subject suitable for treatment with such a composition or dosage form, and methods of improving nutrient absorption using such a composition or dosage form.